Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy

Interventional radiology for local immunotherapy in oncology

(2021) Lambros Tselikas et al.   CLINICAL CANCER RESEARCH

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

(2021) Julia Maria Ressler et al.   Journal for ImmunoTherapy of Cancer

Intratumoural administration and tumour tissue targeting of cancer immunotherapies

(2021) Ignacio Melero et al.   Nature Reviews Clinical Oncology

The Next Decade of Immune Checkpoint Therapy

(2021) Padmanee Sharma et al.   Cancer Discovery

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion

(2020) Maite Alvarez et al.   Frontiers in Immunology

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

(2020) Alain P. Algazi et al.   CLINICAL CANCER RESEARCH

Cellular cytotoxicity is a form of immunogenic cell death

(2020) Luna Minute et al.   Journal for ImmunoTherapy of Cancer

Diverse immune environments in human lung tuberculosis granulomas assessed by quantitative multiplexed immunofluorescence

(2020) Marta Abengozar-Muela et al.   MODERN PATHOLOGY

Intratumoral interleukin-12 mRNA therapy promotes TH1 transformation of the tumor microenvironment

(2020) Susannah L Hewitt et al.   CLINICAL CANCER RESEARCH

Bacteria sting viral invaders

(2020) Justin Jenson et al.   NATURE

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors

(2020) Iván Márquez-Rodas et al.   Science Translational Medicine

Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma

(2020) Anusha Kalbasi et al.   Science Translational Medicine

Clinical landscape of oncolytic virus research in 2020

(2020) Nicholas Macedo et al.   Journal for ImmunoTherapy of Cancer

71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results

(2020) D.P. Zandberg et al.   ANNALS OF ONCOLOGY

Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs

(2019) Susannah L. Hewitt et al.   Science Translational Medicine

cGAS in action: Expanding roles in immunity and inflammation

(2019) Andrea Ablasser et al.   SCIENCE

Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance

(2019) Daisuke Muraoka et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunotherapeutic effects of intratumoral nanoplexed poly I:C

(2019) M. Angela Aznar et al.   Journal for ImmunoTherapy of Cancer

STING pathway agonism as a cancer therapeutic

(2019) Blake A. Flood et al.   IMMUNOLOGICAL REVIEWS

Optimizing oncolytic virotherapy in cancer treatment

(2019) Kevin Harrington et al.   NATURE REVIEWS DRUG DISCOVERY

Pharmacological modulation of nucleic acid sensors — therapeutic potential and persisting obstacles

(2019) Claire Vanpouille-Box et al.   NATURE REVIEWS DRUG DISCOVERY

Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells

(2019) Iñaki Etxeberria et al.   CANCER CELL

Therapeutic Immune Modulation Against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial

(2018) Chrisann Kyi et al.   CLINICAL CANCER RESEARCH

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma

(2018) Matthew J. Frank et al.   Cancer Discovery

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

(2018) Antoni Ribas et al.   Cancer Discovery

LBA15Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas

(2018) K J Harrington et al.   ANNALS OF ONCOLOGY

Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus–Derived Vectors Fosters Dendritic Cell–Mediated T-cell Cross-Priming

(2018) Alfonso R. Sánchez-Paulete et al.   CANCER RESEARCH

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

(2018) Kelsey E. Sivick et al.   Cell Reports

Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally

(2016) M. Angela Aznar et al.   JOURNAL OF IMMUNOLOGY

Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer

(2015) L. Corrales et al.   CLINICAL CANCER RESEARCH

New perspectives on type I IFNs in cancer

(2015) Thomas F. Gajewski et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Control of adaptive immunity by the innate immune system

(2015) Akiko Iwasaki et al.   NATURE IMMUNOLOGY

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

(2015) Leticia Corrales et al.   Cell Reports

Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade

(2015) José I. Quetglas et al.   Cancer Immunology Research

Trimmomatic: a flexible trimmer for Illumina sequence data

(2014) Anthony M. Bolger et al.   BIOINFORMATICS

Intratumoral Immunization: A New Paradigm for Cancer Therapy

(2014) A. Marabelle et al.   CLINICAL CANCER RESEARCH

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

(2014) Seng-Ryong Woo et al.   IMMUNITY

Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer

(2014) Marieke F. Fransen et al.   VACCINE

Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects

(2013) M. F. Fransen et al.   CLINICAL CANCER RESEARCH

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

Novel Murine Dendritic Cell Lines: A Powerful Auxiliary Tool for Dendritic Cell Research

(2012) Silvia A. Fuertes Marraco et al.   Frontiers in Immunology

Direct Effects of Type I Interferons on Cells of the Immune System

(2011) S. Hervas-Stubbs et al.   CLINICAL CANCER RESEARCH

TheN-Ethyl-N-Nitrosourea-InducedGoldenticketMouse Mutant Reveals an Essential Function ofStingin theIn VivoInterferon Response toListeria monocytogenesand Cyclic Dinucleotides

(2010) John-Demian Sauer et al.   INFECTION AND IMMUNITY

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

(2010) Joshua D. Brody et al.   JOURNAL OF CLINICAL ONCOLOGY

Type I IFN controls chikungunya virus via its action on nonhematopoietic cells

(2010) Clémentine Schilte et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Targeted Activation of Innate Immunity for Therapeutic Induction of Autophagy and Apoptosis in Melanoma Cells

(2009) Damià Tormo et al.   CANCER CELL

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy

(2008) R. Houot et al.   BLOOD

Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity

(2008) K. Hildner et al.   SCIENCE